Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

被引：4
|
作者：
Zang, Peter D. [1 ]
Chawla, Neal S. [1 ]
Barragan-Carrillo, Regina [1 ]
Chehrazi-Raffle, Alex [1 ]
Tripathi, Abhishek [1 ]
Pal, Sumanta K. [1 ]
Dorff, Tanya B. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 04期
关键词：
IPILIMUMAB;
D O I：
10.1001/jamaoncol.2023.6817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
引用
收藏
页码：531 / 532
页数：2
相关论文
共 50 条
  • [21] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [22] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [23] Rucaparib in castration-resistant, metastatic prostate cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
  • [24] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
  • [25] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    Mutetwa, Tinaye
    Foulkes, William D.
    Polak, Paz
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 890 - 890
  • [26] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [27] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [28] Circulating Tumor Cells and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer
    Pleskow, H.
    Otani, K.
    Kusaka, E.
    Ukleja, J.
    Balza, R.
    Fisher, R.
    Broderick, K.
    Maheswaran, S.
    Haber, D.
    Saylor, P. J.
    Miyamoto, D. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E534 - E535
  • [29] A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer
    Boiarsky, Daniel
    Tewari, Alok
    Gulhan, Doga
    Bakouny, Ziad
    Ananda, Guruprasad
    Savignano, Hunter
    Lakshminarayana, Gitanjali
    Choueiri, Toni K.
    Taplin, Mary-Ellen
    Berchuk, Jacob E.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [30] A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer
    Boiarsky, Daniel
    Tewari, Alok K.
    Gulhan, Doga C.
    Bakouny, Ziad
    Ananda, Guruprasad
    Savignano, Hunter
    Lakshminarayanan, Gitanjali
    McClure, Heather M.
    Silver, Rebecca
    Choueiri, Toni K.
    Taplin, Mary-Ellen
    Park, Peter J.
    Berchuck, Jacob E.
    PROSTATE, 2024, 84 (16): : 1479 - 1489
12345